Skip to main content
. Author manuscript; available in PMC: 2018 Jul 30.
Published in final edited form as: Psychiatry Res. 2017 Apr 30;265:45–53. doi: 10.1016/j.pscychresns.2017.04.011

Table 6.

Outcome Prediction Results Using Generalized Estimating Equations: High WSWS and Low WSWS Analyzed Separately; Whole Sample

FNC Interaction
Term (TrGrp
by FNC) p
value		 Coefficients for Predictor:
Unstandardized Beta
High WSWS Hypothesized FNC Pairs Insula-dACC 0.758 −0.822
p value = 0.133
Insula-dlPFC 0.840 −0.522
p value = 0.339
Exploratory FNC Pairs with Significant WSWS * FNC Interaction Terms Caudate-dACC 0.818 2.2841
p value = 0.001
Putamen-dACC 0.372 1.6682
p value < 0.001
Low WSWS Hypothesized FNC Pairs Insula-dACC 0.173 −0.598
p value = 0.231
Insula-dlPFC 0.837 −0.266
p value = 0.590
Exploratory FNC Pairs with Significant WSWS * FNC Interaction Terms Caudate-dACC 0.045 Varen 0.912
p value = 0.258
Placebo −0.608
p value = 0.286
Putamen-dACC 0.088 −0.618
p value = 0.274

WSWS = Wisconsin Withdrawal Scale obtained at time of scan, FNC = functional network connectivity. dACC=dorsolateral anterior cingulate cortex, dlPFC = dorsolateral prefrontal cortex, rACC = rostral anterior cingulate cortex. Varen = varenicline. TrGrp = treatment group assignment (varenicline versus placebo).

Only results for exploratory FNC pairs with significant interaction terms (WSWS * FNC) using a Bonferroni correction (p value < .004) listed here. Exploratory FNC pairs with sub-threshold significant findings (0.05>p>0.004) are in supplemental materials, and FNC pairs with no significant findings are not reported. When the interaction terms [FNC value * TrGrp] were significant (p<0.05) models were run in varenicline and placebo groups separately and coefficients for each are presented.

TrGrp, head motion (rmsRot) and number of cigarettes smoked during the 60 days prior to the screen visit (Scr) were included in all models, but coefficients are not generally listed here for simplicity. TrGrp was a significant predictor in all models, Scr was a significant predictor for all models run in the Low WSWS subgroup but not for any of the models run in the High WSWS subgroup, and rmsRot was a significant predictor in individuals with low WSWS on varenicline for rACC-dlPFC (beta = −7.818) and caudate-dACC (beta = −8.344), and in all individuals for putamen-dACC (beta = −3.701).

1

Standardized betas: Scr = 0.179, TrGrp = −0.352, rmsRot = 0.048, Caudate-dACC = 0.426.

2

Standardized betas: Scr = 0.144, TrGrp = −0.329, rmsRot = 0.128, Putamen-dACC = 0.371.